Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Active Rheumatoid Arthritis
NCT00603525Phase 3Terminated
- Sponsor
- GSK
- Start
- Jan 2008
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Ofatumumab with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20% Improvement at 24 weeks. Started Jan 2008; status: terminated.
02
Drugs
ofatumumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00603525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603525.